Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
XB-ART-10287
Peptides 2000 Jul 01;217:1141-6. doi: 10.1016/s0196-9781(00)00252-7.
Show Gene links Show Anatomy links

Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor.

Bloms-Funke P , Gillen C , Schuettler AJ , Wnendt S .


???displayArticle.abstract???
The nociceptin/orphanin FQ (N/OFQ) receptor (e.g. the human ortholog ORL1) has been shown to be pharmacologically distinct from classic opioid receptors. Recently, we have identified buprenorphine as a full ORL1 agonist using a reporter gene assay. For further functional analysis, buprenorphine's effects on ORL1 receptors were investigated using a K(+) channel (GIRK1) assay in Xenopus oocytes and GTPgammaS assay in CHO-K1 membrane preparations. In both assays, buprenorphine behaved as a partial agonist compared to nociceptin itself. The N/OFQ agonism of buprenorphine might contribute to actions of buprenorphine in pain models in vivo beside its mu- or kappa-opioid receptor mediated effects.

???displayArticle.pubmedLink??? 10998549
???displayArticle.link??? Peptides